Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Pelthos Therapeutics Inc.AMEX: PTHS
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $27.52M rose 10909.2% year over year, ahead of the +9047.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 52.7% from the prior quarter. Over 3 fiscal years it compounded at +203.5% a year.
Context
- Financing cash flow amounted to 269.9% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10909.2% holds above the trailing-twelve-month pace of +9047.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 45.34M USD
- Year-over-year change
- +630.1%
- 3-year CAGR
- +203.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.34M | +630.1% |
| FY2024 | 2024-12-31 | 6.21M | +507.4% |
| FY2023 | 2023-12-31 | 1.02M | -37.0% |
| FY2022 | 2022-12-31 | 1.62M | — |
Financing Cash Flow vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's LTM Mar 2026 financing cash flow of $72.61M is the largest of the 4 companies compared; the peer median is $10.99M.
- Its year-over-year change of +9047.0% is the highest of 4, against a peer median of +70.2%.
- Financing cash flow amounts to 262.1% of revenue for PTHS.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $72.61M | +9047.0% | +203.5% | 262.1% | |
| LTM Mar 2026 | $36.15M | +58.2% | +48.8% | — | |
| LTM Dec 2025 | $10.99M | +70.2% | +310.6% | — | |
| LTM Mar 2026 | $9.4M | +927.8% | +26.1% | — | |
| Peer median (excluding PTHS) | $10.99M | +70.2% | +48.8% | — | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Depreciation & Amortization | 0 | 0 | 0 | 2.36M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 0 |
| Change in Working Capital | 640.86K | 2.05M | 34.63K | (6.07M) |
| Accounts Receivables | 0 | 0 | (45.79K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 1.78M |
| Accounts Payables | 413.6K | 1.63M | 1.18M | 1.36M |
| Other Working Capital | 227.26K | 424.07K | (1.1M) | (395K) |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 24.44M |
| Operating Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.59M) |
| Capital Expenditures | 0 | 0 | 0 | (99K) |
| Acquisitions (Net) | 0 | 0 | 0 | (5.14M) |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (5.24M) |
| Debt Repayment | 400K | 766.94K | 321.43K | 17.75M |
| Common Stock Issued | 0 | 255.41K | 6.05M | 27.59M |
| Common Stock Repurchased | 0 | 0 | (166.51K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.02M | 6.21M | 45.34M |
| Effect of Forex Changes | 0 | 0 | 0 | (443) |
| Net Change in Cash | 55.07K | 41.32K | 417.05K | 17.51M |
| Free Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.69M) |
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.